The chemical substance N-[(2S)-1-{[(2S,3S,5S)-5-(butylcarbamoyl)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino}-1-oxopent-4-en-2-yl]-Nα-(morpholin-4-ylsulfonyl)-L-phenylalaninamide, with CAS number 150351-30-7, is a complex organic compound characterized by its multi-functional structure. It features a chiral center, indicating that it exists in two enantiomeric forms, which can have different biological activities. The presence of a morpholine ring suggests potential interactions with biological targets, while the butylcarbamoyl and cyclohexyl groups contribute to its hydrophobic characteristics, influencing solubility and permeability. The compound also contains an amide bond, which is significant for its stability and reactivity. Its specific stereochemistry and functional groups may confer unique pharmacological properties, making it of interest in medicinal chemistry, particularly in the development of therapeutic agents. Overall, this compound exemplifies the complexity often found in drug-like molecules, combining various structural motifs that can affect its biological activity and interactions.

PD 134922 is a novel HIV-1 protease inhibitors identified by rational selection.The human immunodeficiency virus (HIV-1), associated with the AIDS (acquired immunodeficiency syndrome) epidemic, encodes an aspartyl protease that is essential for polyprotein processing in the virus (Navia et al., 1989). It has been demonstrated that inactivation of the protease either catalytically or by an inhibitor prevents infectious virion formation (Kohl et al., 1988; Darke et al., 1989). The acquired knowledge of key molecular interactions occurring between inhibitors and aspartyl proteases, as well as the structural similarities between HIV-1 protease and human renin was used to rationally select candidates for HIV-1 screening from the pool of analogs designed as renin inhibitors. A minimal number of chosen compounds were tested in an HIV-1 protease assay system. Two structurally novel peptides emerged as potent enzymatic protease inhibitors.

N-[(2S)-1-{[(2S,3S,5S)-5-(butylcarbamoyl)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino}-1-oxopent-4-en-2-yl]-Nalpha-(morpholin-4-ylsulfonyl)-L-phenylalaninamide

150351-30-7: The chemical substance N-[(2S)-1-{[(2S,3S,5S)-5-(butylcarbamoyl)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino}-1-oxopent-4-en-2-yl]-Nα-(morpholin-4-ylsulfonyl)-L-phenylalaninamide, with CAS number 150351-30-7, is a complex organic compound characterized by its multi-functional structure. It features a chiral center, indicating that it exists in two enantiomeric forms, which can have different biological activities. The presence of a morpholine ring suggests potential interactions with biological targets, while the butylcarbamoyl and cyclohexyl groups contribute to its hydrophobic characteristics, influencing solubility and permeability. The compound also contains an amide bond, which is significant for its stability and reactivity. Its specific stereochemistry and functional groups may confer unique pharmacological properties, making it of interest in medicinal chemistry, particularly in the development of therapeutic agents. Overall, this compound exemplifies the complexity often found in drug-like molecules, combining various structural motifs that can affect its biological activity and interactions.

PD 134922 is a HIV-1 protease inhibitors. Inactivation of the protease prevents infectious virion formation.

CAS 150351-30-7

N-[(2S)-1-{[(2S,3S,5S)-5-(butylcarbamoyl)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino}-1-oxopent-4-en-2-yl]-Nalpha-(morpholin-4-ylsulfonyl)-L-phenylalaninamide

PD 134922

Ref: TM-T28329